Oxygen enhancing membrane systems for implantable devices
First Claim
1. An electrochemical sensor for determining a presence or a concentration of an analyte in a fluid, the sensor comprising:
- a membrane system comprising an enzyme domain comprising an enzyme that reacts with the analyte in the fluid as it passes through the enzyme domain; and
a working electrode comprising a conductive material, wherein the working electrode is configured to measure a product of a reaction of the enzyme with the analyte, wherein the membrane system comprises a polymer material with a high oxygen solubility.
2 Assignments
0 Petitions

Accused Products

Abstract
The present invention relates generally to systems and methods for increasing oxygen availability to implantable devices. The preferred embodiments provide a membrane system configured to provide protection of the device from the biological environment and/or a catalyst for enabling an enzymatic reaction, wherein the membrane system includes a polymer formed from a high oxygen soluble material. The high oxygen soluble polymer material is disposed adjacent to an oxygen-utilizing source on the implantable device so as to dynamically retain high oxygen availability to the oxygen-utilizing source during oxygen deficits. Membrane systems of the preferred embodiments are useful for implantable devices with oxygen-utilizing sources and/or that function in low oxygen environments, such as enzyme-based electrochemical sensors and cell transplantation devices.
651 Citations
Method of Calibrating an Analyte-Measurement Device, and Associated Methods, Devices and Systems | ||
Patent #
US 20110004084A1
Filed 09/17/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,885,699 B2
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Biointerface membranes incorporating bioactive agents | ||
Patent #
US 7,875,293 B2
Filed 05/10/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Anti-Coagulant Calibrant Infusion Fluid Source | ||
Patent #
US 20110054284A1
Filed 08/28/2009
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 7,917,186 B2
Filed 11/16/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 7,884,729 B2
Filed 08/02/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,885,697 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Optimized sensor geometry for an implantable glucose sensor | ||
Patent #
US 7,881,763 B2
Filed 05/02/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,914,450 B2
Filed 05/03/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,905,833 B2
Filed 06/21/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,896,809 B2
Filed 11/03/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,869,853 B1
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 7,922,458 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,955,261 B2
Filed 03/23/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,946,984 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and System for Providing Continuous Calibration of Implantable Analyte Sensors | ||
Patent #
US 20110130639A1
Filed 02/07/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,949,381 B2
Filed 04/11/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,933,639 B2
Filed 03/23/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and method | ||
Patent #
US 7,920,907 B2
Filed 06/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 7,928,850 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 7,920,906 B2
Filed 03/09/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,925,321 B2
Filed 03/23/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,959,569 B2
Filed 03/23/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 7,935,057 B2
Filed 01/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,970,448 B2
Filed 04/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated receiver for continuous analyte sensor | ||
Patent #
US 7,927,274 B2
Filed 07/29/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,010,174 B2
Filed 08/22/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 7,993,109 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 7,993,108 B2
Filed 04/13/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Blood glucose tracking apparatus | ||
Patent #
US 7,976,778 B2
Filed 06/22/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 7,998,071 B2
Filed 10/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,005,525 B2
Filed 10/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,000,901 B2
Filed 08/09/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,986,986 B2
Filed 03/23/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,005,524 B2
Filed 03/24/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated delivery device for continuous glucose sensor | ||
Patent #
US 7,976,492 B2
Filed 08/06/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,974,672 B2
Filed 04/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,979,104 B2
Filed 05/26/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,052,601 B2
Filed 08/20/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 8,053,018 B2
Filed 01/15/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Protrudent analyte sensor | ||
Patent #
US 8,032,198 B2
Filed 02/07/2006
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Method and system for providing integrated medication infusion and analyte monitoring system | ||
Patent #
US 8,029,460 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,029,245 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 8,066,639 B2
Filed 06/04/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,060,173 B2
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 8,050,731 B2
Filed 11/16/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,047,812 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing integrated medication infusion and analyte monitoring system | ||
Patent #
US 8,029,459 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,047,811 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,029,250 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,860,544 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
MEMBRANE FOR USE WITH IMPLANTABLE DEVICES | ||
Patent #
US 20100087724A1
Filed 12/08/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane For Use With Amperometric Sensors | ||
Patent #
US 20100072062A1
Filed 05/05/2009
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
Device and method for determining analyte levels | ||
Patent #
US 7,792,562 B2
Filed 12/22/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 7,811,231 B2
Filed 12/26/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,774,145 B2
Filed 01/18/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing peak detection circuitry for data communication systems | ||
Patent #
US 7,679,407 B2
Filed 04/27/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
CELLULOSIC-BASED INTERFERENCE DOMAIN FOR AN ANALYTE SENSOR | ||
Patent #
US 20100121169A1
Filed 01/21/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 7,715,893 B2
Filed 12/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
CALIBRATION TECHNIQUES FOR A CONTINUOUS ANALYTE SENSOR | ||
Patent #
US 20100063373A1
Filed 11/16/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 7,766,829 B2
Filed 11/04/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,831,287 B2
Filed 04/28/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,835,777 B2
Filed 12/22/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing rechargeable power in data monitoring and management systems | ||
Patent #
US 7,756,561 B2
Filed 09/30/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 7,768,408 B2
Filed 05/17/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,826,981 B2
Filed 01/18/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Implantable analyte sensor | ||
Patent #
US 7,657,297 B2
Filed 05/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,797,028 B2
Filed 04/14/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,713,574 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Cellulosic-based interference domain for an analyte sensor | ||
Patent #
US 7,651,596 B2
Filed 01/18/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
ANALYTE SENSOR APPARATUSES COMPRISING MULTIPLE IMPLANTABLE SENSOR ELEMENTS AND METHODS FOR MAKING AND USING THEM | ||
Patent #
US 20100030045A1
Filed 07/31/2008
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
ANALYTE SENSOR APPARATUSES HAVING IMPROVED ELECTRODE CONFIGURATIONS AND METHODS FOR MAKING AND USING THEM | ||
Patent #
US 20100025238A1
Filed 07/31/2008
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,654,956 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte Sensor with Non-Working Electrode Layer | ||
Patent #
US 20100108509A1
Filed 10/30/2009
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
Transcutaneous medical device with variable stiffness | ||
Patent #
US 7,783,333 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte Sensor and Fabrication Methods | ||
Patent #
US 20100200538A1
Filed 02/03/2010
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,778,680 B2
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte Sensor | ||
Patent #
US 20100243477A1
Filed 08/26/2009
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
Analyte sensor | ||
Patent #
US 7,828,728 B2
Filed 02/14/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 7,857,760 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte measuring device | ||
Patent #
US 7,860,545 B2
Filed 02/26/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,494,465 B2
Filed 06/21/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICES | ||
Patent #
US 20090045055A1
Filed 10/28/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,497,827 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
DUAL ELECTRODE SYSTEM FOR A CONTINUOUS ANALYTE SENSOR | ||
Patent #
US 20090076356A1
Filed 11/03/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated receiver for continuous analyte sensor | ||
Patent #
US 7,519,408 B2
Filed 11/17/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
ANALYTE SENSOR | ||
Patent #
US 20090143658A1
Filed 08/27/2008
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
BLOOD CONTACTING SENSOR | ||
Patent #
US 20090149728A1
Filed 11/04/2008
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,583,990 B2
Filed 04/14/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated delivery device for continuous glucose sensor | ||
Patent #
US 7,591,801 B2
Filed 02/26/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 7,599,726 B2
Filed 04/14/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method of Calibrating an Analyte-Measurement Device, and Associated Methods, Devices and Systems | ||
Patent #
US 20090265129A1
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method of Calibrating an Analyte-Measurement Device, and Associated Methods, Devices and Systems | ||
Patent #
US 20090265130A1
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
POLYMER MEMBRANES FOR CONTINUOUS ANALYTE SENSORS | ||
Patent #
US 20090247856A1
Filed 03/27/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
ANALYTE SENSOR | ||
Patent #
US 20090242399A1
Filed 03/25/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 7,620,438 B2
Filed 03/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
CONTINUOUS MEDICAMENT SENSOR SYSTEM FOR IN VIVO USE | ||
Patent #
US 20090299156A1
Filed 02/04/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane for use with implantable devices | ||
Patent #
US 7,632,228 B2
Filed 01/29/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR | ||
Patent #
US 20090299276A1
Filed 08/06/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 7,640,048 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Composite material for implantable device | ||
Patent #
US 7,637,868 B2
Filed 01/11/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,366,556 B2
Filed 10/04/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Biointerface membrane with macro-and micro-architecture | ||
Patent #
US 7,364,592 B2
Filed 02/09/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA | ||
Patent #
US 20080183061A1
Filed 04/04/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20080194935A1
Filed 04/11/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA | ||
Patent #
US 20080195967A1
Filed 04/14/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA | ||
Patent #
US 20080194937A1
Filed 04/14/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
BIOINTERFACE WITH MACRO- AND MICRO-ARCHITECTURE | ||
Patent #
US 20080195232A1
Filed 04/15/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
DUAL ELECTRODE SYSTEM FOR A CONTINUOUS ANALYTE SENSOR | ||
Patent #
US 20080214918A1
Filed 04/28/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,424,318 B2
Filed 10/04/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
INTEGRATED MEDICAMENT DELIVERY DEVICE FOR USE WITH CONTINUOUS ANALYTE SENSOR | ||
Patent #
US 20080262469A1
Filed 06/05/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR | ||
Patent #
US 20080287766A1
Filed 07/29/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,467,003 B2
Filed 10/04/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,460,898 B2
Filed 10/04/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 20070027384A1
Filed 10/04/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing analyte sensor data | ||
Patent #
US 20070066873A1
Filed 09/01/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membranes for an analyte sensor | ||
Patent #
US 20070173709A1
Filed 01/17/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte Sensor, and Associated System and Method Employing a Catalytic Agent | ||
Patent #
US 20070191701A1
Filed 04/11/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 20070232879A1
Filed 05/03/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 20070265515A1
Filed 05/03/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Methods and systems for inserting a transcutaneous analyte sensor | ||
Patent #
US 7,310,544 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20060020189A1
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20060019327A1
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20060020187A1
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20060036145A1
Filed 06/21/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20060040402A1
Filed 08/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Paul V. Goode Jr., Apurv U. Kamath, James H. Brauker
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20060036139A1
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20060036141A1
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for improving electrochemical analyte sensors | ||
Patent #
US 7,081,195 B2
Filed 12/07/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Electrode systems for electrochemical sensors | ||
Patent #
US 7,074,307 B2
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Electrochemical sensors including electrode systems with increased oxygen generation | ||
Patent #
US 7,108,778 B2
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Optimized sensor geometry for an implantable glucose sensor | ||
Patent #
US 20060211921A1
Filed 05/02/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 20060258761A1
Filed 04/14/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 20060249381A1
Filed 04/28/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 20060252027A1
Filed 04/28/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Protrudent analyte sensor | ||
Patent #
US 20060293576A1
Filed 02/07/2006
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 20050043598A1
Filed 08/22/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte measuring device | ||
Patent #
US 20050033132A1
Filed 05/14/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027180A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027463A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Rolled electrode array and its method for manufacture | ||
Patent #
US 20050051427A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Electrochemical sensors including electrode systems with increased oxygen generation | ||
Patent #
US 20050051440A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Electrode systems for electrochemical sensors | ||
Patent #
US 20050115832A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Peter C. Simpson, James R. Petisce, Victoria Carr-Brendel, James H. Brauker
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 20050143635A1
Filed 12/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR | ||
Patent #
US 20050154271A1
Filed 11/17/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for improving electrochemical analyte sensors | ||
Patent #
US 20050161346A1
Filed 12/07/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
SYSTEM AND METHOD FOR PROCESSING ANALYTE SENSOR DATA | ||
Patent #
US 20050187720A1
Filed 01/18/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
AFINITY DOMAIN FOR ANALYTE SENSOR | ||
Patent #
US 20050176136A1
Filed 11/16/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Implantable device with improved radio frequency capabilities | ||
Patent #
US 20050182451A1
Filed 01/11/2005
|
Current Assignee
Sean Saint, Adam Griffin, Mark Brister
|
Original Assignee
Sean Saint, Adam Griffin, Mark Brister
|
INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR | ||
Patent #
US 20050192557A1
Filed 02/26/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Dexcom Retail BV
|
IMPLANTABLE ANALYTE SENSOR | ||
Patent #
US 20050242479A1
Filed 05/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
IMPLANTABLE ANALYTE SENSOR | ||
Patent #
US 20050245795A1
Filed 05/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
IMPLANTABLE ANALYTE SENSOR | ||
Patent #
US 20050245799A1
Filed 05/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Biointerface with macro-and micro-architecture | ||
Patent #
US 20050251083A1
Filed 02/09/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane for use with implantable devices | ||
Patent #
US 20040186362A1
Filed 01/29/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 8,123,686 B2
Filed 03/01/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 8,064,977 B2
Filed 07/29/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method of calibrating of an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,116,840 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US RE43,039 E1
Filed 07/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 8,089,363 B2
Filed 02/07/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,073,519 B2
Filed 10/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,073,520 B2
Filed 05/25/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and device for early signal attenuation detection using blood glucose measurements | ||
Patent #
US 8,103,456 B2
Filed 01/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing rechargeable power in data monitoring and management systems | ||
Patent #
US 8,112,138 B2
Filed 09/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing leak detection in data monitoring and management systems | ||
Patent #
US 8,112,240 B2
Filed 04/29/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,128,562 B2
Filed 10/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,149,117 B2
Filed 08/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,150,488 B2
Filed 10/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,160,669 B2
Filed 04/11/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,160,671 B2
Filed 09/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,162,829 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,167,801 B2
Filed 03/25/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,170,803 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,175,673 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,177,716 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electrode systems for electrochemical sensors | ||
Patent #
US RE43,399 E1
Filed 06/13/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 8,187,183 B2
Filed 10/11/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,195,265 B2
Filed 02/09/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,206,297 B2
Filed 12/16/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method of calibrating an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,219,175 B2
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method of calibrating an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,219,174 B2
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,216,139 B2
Filed 09/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,224,413 B2
Filed 10/10/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,558 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,557 B2
Filed 12/28/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,555 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 8,226,891 B2
Filed 03/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,229,536 B2
Filed 05/27/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,229,534 B2
Filed 10/26/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for blood glucose monitoring and alert delivery | ||
Patent #
US 8,229,535 B2
Filed 02/20/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 8,231,531 B2
Filed 06/01/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,231,532 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing analyte sensor data | ||
Patent #
US 8,233,959 B2
Filed 09/01/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,233,958 B2
Filed 10/12/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood glucose tracking apparatus and methods | ||
Patent #
US 8,236,242 B2
Filed 02/12/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,235,896 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,249,684 B2
Filed 09/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,251,906 B2
Filed 04/15/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,032 B2
Filed 01/15/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,030 B2
Filed 04/25/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,255,031 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,033 B2
Filed 04/25/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,257,259 B2
Filed 10/16/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,260,392 B2
Filed 06/09/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal data artifacts in a glucose sensor data stream | ||
Patent #
US 8,260,393 B2
Filed 06/13/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,265,726 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,265,725 B2
Filed 10/12/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood glucose tracking apparatus and methods | ||
Patent #
US 8,268,243 B2
Filed 12/28/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,273,022 B2
Filed 02/13/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,275,439 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,275,437 B2
Filed 03/23/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Implantable analyte sensor | ||
Patent #
US 8,277,713 B2
Filed 05/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,280,475 B2
Filed 02/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated receiver for continuous analyte sensor | ||
Patent #
US 8,282,550 B2
Filed 07/29/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,282,549 B2
Filed 12/08/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,285,354 B2
Filed 03/23/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,287,454 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,287,453 B2
Filed 11/07/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 8,290,559 B2
Filed 10/24/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,290,560 B2
Filed 11/18/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,290,561 B2
Filed 09/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,290,562 B2
Filed 05/03/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,292,810 B2
Filed 01/27/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,306,598 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,311,749 B2
Filed 05/26/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor inserter system | ||
Patent #
US 8,313,434 B2
Filed 03/01/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,321,149 B2
Filed 06/29/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,332,008 B2
Filed 03/23/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Fluid delivery device with autocalibration | ||
Patent #
US 8,343,093 B2
Filed 05/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing integrated medication infusion and analyte monitoring system | ||
Patent #
US 8,343,092 B2
Filed 11/24/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing a fault tolerant display unit in an electronic device | ||
Patent #
US 8,344,966 B2
Filed 01/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,336 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,337 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,346,338 B2
Filed 01/27/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood contacting sensor | ||
Patent #
US 8,352,011 B2
Filed 11/04/2008
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,353,829 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,357,091 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,362,904 B2
Filed 04/18/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,366,614 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 8,369,919 B2
Filed 10/24/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,372,005 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,374,667 B2
Filed 10/16/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,380,273 B2
Filed 04/11/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,386,004 B2
Filed 09/07/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,391,945 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,394,021 B2
Filed 10/01/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,409,131 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,412,301 B2
Filed 02/09/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 8,423,113 B2
Filed 10/24/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,423,114 B2
Filed 10/01/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,428,678 B2
Filed 05/16/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,428,679 B2
Filed 03/26/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,435,179 B2
Filed 01/27/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,442,610 B2
Filed 08/21/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,452,368 B2
Filed 01/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,456,301 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,457,708 B2
Filed 12/05/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,461,985 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,463,350 B2
Filed 05/14/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,465,425 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop blood glucose control algorithm analysis | ||
Patent #
US 8,467,972 B2
Filed 04/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,469,886 B2
Filed 09/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 8,471,714 B2
Filed 12/30/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for early signal attenuation detection using blood glucose measurements | ||
Patent #
US 8,473,220 B2
Filed 01/23/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,473,021 B2
Filed 07/31/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,474,397 B2
Filed 05/06/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,475,373 B2
Filed 07/17/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,480,580 B2
Filed 04/19/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,483,791 B2
Filed 04/11/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,483,793 B2
Filed 10/29/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,491,474 B2
Filed 01/27/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing continuous calibration of implantable analyte sensors | ||
Patent #
US 8,506,482 B2
Filed 02/07/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 8,509,871 B2
Filed 10/28/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing peak detection circuitry for data communication systems | ||
Patent #
US 8,512,246 B2
Filed 03/15/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 8,512,239 B2
Filed 04/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,515,519 B2
Filed 02/26/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,515,516 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 8,527,025 B1
Filed 11/22/1999
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 8,543,184 B2
Filed 10/20/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,548,551 B2
Filed 05/14/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,548,553 B2
Filed 06/22/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 8,560,039 B2
Filed 09/17/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 8,560,037 B2
Filed 03/26/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Computerized determination of insulin pump therapy parameters using real time and retrospective data processing | ||
Patent #
US 8,560,082 B2
Filed 01/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,565,849 B2
Filed 05/14/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,565,848 B2
Filed 05/07/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated medicament delivery device for use with continuous analyte sensor | ||
Patent #
US 8,562,558 B2
Filed 06/05/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,571,625 B2
Filed 05/14/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 8,579,816 B2
Filed 01/07/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Infusion devices and methods | ||
Patent #
US 8,579,853 B2
Filed 10/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,583,204 B2
Filed 03/05/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 8,585,591 B2
Filed 07/10/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,588,882 B2
Filed 12/16/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for customizing delivery of sensor data | ||
Patent #
US 8,591,455 B2
Filed 02/20/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,593,287 B2
Filed 07/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 8,593,109 B2
Filed 11/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,597,189 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 8,597,575 B2
Filed 07/23/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method for detecting an analyte in blood | ||
Patent #
US 8,600,470 B2
Filed 09/15/2011
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,612,159 B2
Filed 02/16/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,615,282 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 8,611,978 B2
Filed 01/07/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,617,071 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 8,622,903 B2
Filed 05/25/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,622,905 B2
Filed 12/11/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,622,906 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US RE44,695 E1
Filed 05/01/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing data communication in data monitoring and management systems | ||
Patent #
US 8,638,220 B2
Filed 05/23/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,641,619 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 8,647,269 B2
Filed 04/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,649,841 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,652,043 B2
Filed 07/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 8,653,977 B2
Filed 06/21/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,657,745 B2
Filed 10/16/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing analyte sensor data | ||
Patent #
US 8,657,747 B2
Filed 04/05/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,660,627 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,663,109 B2
Filed 03/29/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 8,665,091 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,666,469 B2
Filed 11/16/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,668,645 B2
Filed 01/03/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,670,815 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,672,844 B2
Filed 02/27/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing analyte sensor data | ||
Patent #
US 8,672,845 B2
Filed 03/25/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,676,287 B2
Filed 12/11/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and device for early signal attenuation detection using blood glucose measurements | ||
Patent #
US 8,676,513 B2
Filed 06/21/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 8,676,288 B2
Filed 06/22/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,682,408 B2
Filed 03/05/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method of calibrating an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,684,930 B2
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,688,188 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,690,775 B2
Filed 04/11/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor and fabrication methods | ||
Patent #
US 8,696,917 B2
Filed 02/03/2010
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
Analyte sensor apparatuses comprising multiple implantable sensor elements and methods for making and using them | ||
Patent #
US 8,700,114 B2
Filed 07/31/2008
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,700,117 B2
Filed 12/08/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated delivery device for continuous glucose sensor | ||
Patent #
US 8,721,585 B2
Filed 03/30/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Dex Com Inc.
|
Transcutaneous analyte sensor | ||
Patent #
US 8,731,630 B2
Filed 03/22/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing contextual based medication dosage determination | ||
Patent #
US 8,732,188 B2
Filed 02/15/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,348 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,346 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,738,109 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 8,744,546 B2
Filed 04/28/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,744,545 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,747,315 B2
Filed 09/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 8,750,955 B2
Filed 11/02/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
ANALYTE SENSOR AND FABRICATION METHODS | ||
Patent #
US 20140166612A1
Filed 02/20/2014
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,761,856 B2
Filed 04/27/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood glucose tracking apparatus | ||
Patent #
US 8,765,059 B2
Filed 10/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,771,187 B2
Filed 05/31/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 8,771,183 B2
Filed 02/16/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,774,888 B2
Filed 01/20/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,774,887 B2
Filed 03/24/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,777,853 B2
Filed 04/04/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,788,006 B2
Filed 12/11/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,788,008 B2
Filed 05/31/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,788,007 B2
Filed 03/08/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,790,260 B2
Filed 10/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,792,954 B2
Filed 03/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,792,955 B2
Filed 06/09/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,792,953 B2
Filed 03/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,795,177 B2
Filed 01/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Real time management of data relating to physiological control of glucose levels | ||
Patent #
US 8,798,934 B2
Filed 07/23/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,801,612 B2
Filed 04/27/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 8,801,610 B2
Filed 07/24/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated medicament delivery device for use with continuous analyte sensor | ||
Patent #
US 8,808,228 B2
Filed 06/05/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,808,182 B2
Filed 04/27/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous medical device with variable stiffness | ||
Patent #
US 8,812,072 B2
Filed 04/17/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,812,073 B2
Filed 06/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,821,400 B2
Filed 02/09/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,825,127 B2
Filed 05/14/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane for use with implantable devices | ||
Patent #
US 8,840,552 B2
Filed 12/08/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,840,553 B2
Filed 02/26/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 8,843,187 B2
Filed 06/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,858,434 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
MEMBRANE FOR CONTINUOUS ANALYTE SENSORS | ||
Patent #
US 20140275896A1
Filed 03/15/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 8,865,249 B2
Filed 09/28/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,880,137 B2
Filed 04/18/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,886,273 B2
Filed 11/07/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 8,886,272 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 8,900,431 B2
Filed 08/25/2009
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,909,314 B2
Filed 07/20/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,911,369 B2
Filed 12/15/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,915,849 B2
Filed 02/03/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,915,850 B2
Filed 03/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,920,319 B2
Filed 12/28/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated delivery device for continuous glucose sensor | ||
Patent #
US 8,926,585 B2
Filed 03/30/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Multi-function analyte test device and methods therefor | ||
Patent #
US 8,930,203 B2
Filed 02/03/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 8,933,664 B2
Filed 11/25/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,954,128 B2
Filed 10/18/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,974,386 B2
Filed 11/01/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,989,833 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods for managing power and noise | ||
Patent #
US 8,993,331 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,000,929 B2
Filed 11/22/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,332 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,331 B2
Filed 12/29/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,014,773 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing, transmitting and displaying sensor data | ||
Patent #
US 9,020,572 B2
Filed 09/10/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,035,767 B2
Filed 05/30/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 9,039,975 B2
Filed 12/02/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,042,953 B2
Filed 03/02/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,044,199 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,055,901 B2
Filed 09/14/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,060,742 B2
Filed 03/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Infusion devices and methods | ||
Patent #
US 9,064,107 B2
Filed 09/30/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,695 B2
Filed 04/12/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,697 B2
Filed 10/27/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for early signal attenuation detection using blood glucose measurements | ||
Patent #
US 9,066,709 B2
Filed 03/17/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,694 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,072,477 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,078,607 B2
Filed 06/17/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 9,078,608 B2
Filed 07/13/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 9,095,290 B2
Filed 02/27/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,107,623 B2
Filed 04/15/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,135,402 B2
Filed 10/24/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing, transmitting and displaying sensor data | ||
Patent #
US 9,143,569 B2
Filed 02/20/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,149,234 B2
Filed 06/13/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,149,219 B2
Filed 02/09/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,149,233 B2
Filed 06/13/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,173,607 B2
Filed 01/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,177,456 B2
Filed 06/10/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,173,606 B2
Filed 01/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 9,179,869 B2
Filed 09/10/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,192,328 B2
Filed 09/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 9,220,449 B2
Filed 07/09/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Error detection in critical repeating data in a wireless sensor system | ||
Patent #
US 9,226,701 B2
Filed 04/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 9,247,900 B2
Filed 06/04/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,247,901 B2
Filed 08/02/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Sensor and method for removing interfering substance | ||
Patent #
US 9,271,671 B2
Filed 03/28/2011
|
Current Assignee
ARKRAY Inc
|
Original Assignee
ARKRAY Inc
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,282,925 B2
Filed 03/25/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 9,314,196 B2
Filed 09/07/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,314,198 B2
Filed 04/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte signal processing device and methods | ||
Patent #
US 9,314,195 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing notification function in analyte monitoring systems | ||
Patent #
US 9,320,461 B2
Filed 09/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 9,323,898 B2
Filed 11/15/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,716 B2
Filed 12/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 9,328,371 B2
Filed 07/16/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,714 B2
Filed 06/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 9,332,944 B2
Filed 01/31/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,339,238 B2
Filed 05/16/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,339,223 B2
Filed 12/30/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 9,339,222 B2
Filed 05/31/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,351,668 B2
Filed 10/12/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,364,173 B2
Filed 09/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 9,380,971 B2
Filed 12/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,414,777 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,420,965 B2
Filed 07/01/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,420,968 B2
Filed 04/04/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,427,183 B2
Filed 07/12/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,439,589 B2
Filed 11/25/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Methods and systems for promoting glucose management | ||
Patent #
US 9,446,194 B2
Filed 03/26/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 9,451,908 B2
Filed 12/19/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood glucose tracking apparatus and methods | ||
Patent #
US 9,477,811 B2
Filed 06/23/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,498,159 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,498,155 B2
Filed 10/16/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 9,504,413 B2
Filed 04/15/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,510,782 B2
Filed 04/04/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane for use with implantable devices | ||
Patent #
US 9,532,741 B2
Filed 07/25/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated receiver for continuous analyte sensor | ||
Patent #
US 9,538,946 B2
Filed 03/25/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 9,549,693 B2
Filed 07/25/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,549,699 B2
Filed 10/17/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,566,026 B2
Filed 10/17/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,572,523 B2
Filed 09/22/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 9,574,914 B2
Filed 03/03/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 9,579,053 B2
Filed 03/26/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,585,607 B2
Filed 04/04/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 9,597,027 B2
Filed 10/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,603,557 B2
Filed 05/13/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,610,034 B2
Filed 11/09/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 9,625,413 B2
Filed 05/19/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor and method for removing interfering substance | ||
Patent #
US 9,638,657 B2
Filed 01/08/2016
|
Current Assignee
ARKRAY Inc
|
Original Assignee
ARKRAY Inc
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,649,069 B2
Filed 06/29/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,649,057 B2
Filed 05/11/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor and method for removing interfering substance | ||
Patent #
US 9,651,516 B2
Filed 01/08/2016
|
Current Assignee
ARKRAY Inc
|
Original Assignee
ARKRAY Inc
|
Analyte sensor | ||
Patent #
US 9,668,677 B2
Filed 10/26/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 9,669,162 B2
Filed 03/16/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,693,721 B2
Filed 06/17/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,717,449 B2
Filed 01/15/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,724,045 B1
Filed 04/06/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 9,730,584 B2
Filed 02/10/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Membrane for continuous analyte sensors | ||
Patent #
US 9,737,250 B2
Filed 03/15/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated medicament delivery device for use with continuous analyte sensor | ||
Patent #
US 9,741,139 B2
Filed 08/09/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 9,743,863 B2
Filed 06/01/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 9,750,440 B2
Filed 04/12/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing notification function in analyte monitoring systems | ||
Patent #
US 9,750,439 B2
Filed 04/08/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,750,441 B2
Filed 08/15/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,750,460 B2
Filed 04/14/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,775,543 B2
Filed 12/30/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Zwitterion surface modifications for continuous sensors | ||
Patent #
US 9,788,765 B2
Filed 02/27/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 9,801,574 B2
Filed 10/05/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 9,801,545 B2
Filed 07/30/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,801,572 B2
Filed 06/18/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 9,804,114 B2
Filed 03/02/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,833,143 B2
Filed 06/05/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,833,176 B2
Filed 07/12/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,839,395 B2
Filed 10/24/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 9,895,089 B2
Filed 05/20/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,901,307 B2
Filed 12/30/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 9,918,668 B2
Filed 03/09/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,931,067 B2
Filed 09/13/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Zwitterion surface modifications for continuous sensors | ||
Patent #
US 9,936,909 B2
Filed 03/14/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated delivery device for continuous glucose sensor | ||
Patent #
US 9,937,293 B2
Filed 08/19/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 9,949,678 B2
Filed 02/16/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 9,962,091 B2
Filed 01/06/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte signal processing device and methods | ||
Patent #
US 9,968,302 B2
Filed 04/04/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems | ||
Patent #
US 9,968,306 B2
Filed 10/21/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods | ||
Patent #
US 9,980,669 B2
Filed 11/07/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 9,986,942 B2
Filed 08/10/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 9,993,186 B2
Filed 02/09/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Infusion devices and methods | ||
Patent #
US 10,007,759 B2
Filed 06/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 10,022,078 B2
Filed 05/23/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,028,683 B2
Filed 10/07/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,028,684 B2
Filed 09/21/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane for use with implantable devices | ||
Patent #
US 10,039,480 B2
Filed 02/11/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 10,039,881 B2
Filed 07/07/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Zwitterion surface modifications for continuous sensors | ||
Patent #
US 10,045,723 B2
Filed 11/17/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 10,052,051 B2
Filed 10/27/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing continuous calibration of implantable analyte sensors | ||
Patent #
US 10,117,614 B2
Filed 09/11/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 10,136,844 B2
Filed 11/18/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 10,143,410 B2
Filed 06/01/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 10,154,807 B2
Filed 09/27/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 10,178,954 B2
Filed 05/09/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 10,182,751 B2
Filed 06/26/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,201,301 B2
Filed 04/18/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 10,206,611 B2
Filed 08/23/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,231,654 B2
Filed 06/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated medicament delivery device for use with continuous analyte sensor | ||
Patent #
US 10,278,580 B2
Filed 06/09/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 10,299,712 B2
Filed 09/05/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 10,300,507 B2
Filed 02/14/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,314,525 B2
Filed 01/06/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 10,327,638 B2
Filed 10/30/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor apparatuses comprising multiple implantable sensor elements and methods for making and using them | ||
Patent #
US 10,327,678 B2
Filed 04/08/2014
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Method and apparatus for providing notification function in analyte monitoring systems | ||
Patent #
US 10,349,874 B2
Filed 08/31/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 10,349,873 B2
Filed 04/27/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated medicament delivery device for use with continuous analyte sensor | ||
Patent #
US 10,403,012 B2
Filed 07/18/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane for continuous analyte sensors | ||
Patent #
US 10,413,227 B2
Filed 07/18/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods for managing power and noise | ||
Patent #
US 10,429,250 B2
Filed 03/26/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,478,108 B2
Filed 02/05/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 10,506,982 B2
Filed 05/22/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 10,524,703 B2
Filed 01/24/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Methods and systems for promoting glucose management | ||
Patent #
US 10,537,678 B2
Filed 12/16/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,137 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,136 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 10,610,140 B2
Filed 05/11/2018
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,135 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Methods and systems for promoting glucose management | ||
Patent #
US 10,610,642 B2
Filed 12/30/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,617,336 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 10,653,317 B2
Filed 01/10/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated insulin delivery system with continuous glucose sensor | ||
Patent #
US 10,653,835 B2
Filed 10/24/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Methods and systems for simulating glucose response to simulated actions | ||
Patent #
US 10,675,405 B2
Filed 12/04/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,709,364 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,709,362 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,709,363 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,716,498 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,722,152 B2
Filed 11/05/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,743,801 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 10,750,952 B2
Filed 03/26/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 10,786,185 B2
Filed 01/05/2018
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,799,158 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,799,159 B2
Filed 02/13/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,813,577 B2
Filed 02/13/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,813,576 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 10,827,980 B2
Filed 05/16/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated insulin delivery system with continuous glucose sensor | ||
Patent #
US 10,835,672 B2
Filed 05/05/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,856,787 B2
Filed 07/31/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Real time management of data relating to physiological control of glucose levels | ||
Patent #
US 10,872,102 B2
Filed 08/01/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
BIOLOGICAL FUEL CELL AND METHODS | ||
Patent #
US 20060159981A1
Filed 03/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 20060258761A1
Filed 04/14/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 20050043598A1
Filed 08/22/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Biointerface membranes incorporating bioactive agents | ||
Patent #
US 20050031689A1
Filed 05/10/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte measuring device | ||
Patent #
US 20050033132A1
Filed 05/14/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027181A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027180A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027463A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Rolled electrode array and its method for manufacture | ||
Patent #
US 20050051427A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Electrochemical sensors including electrode systems with increased oxygen generation | ||
Patent #
US 20050051440A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Increasing bias for oxygen production in an electrode system | ||
Patent #
US 20050056552A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 6,862,465 B2
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone composition for biocompatible membrane | ||
Patent #
US 20050090607A1
Filed 10/28/2003
|
Current Assignee
DECOM INC.
|
Original Assignee
DexCom Incorporated
|
INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR | ||
Patent #
US 20050192557A1
Filed 02/26/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Dexcom Retail BV
|
Membrane for use with implantable devices | ||
Patent #
US 6,702,857 B2
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane and electrode structure for implantable sensor | ||
Patent #
US 6,721,587 B2
Filed 02/15/2002
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Device and method for determining analyte levels | ||
Patent #
US 6,741,877 B1
Filed 01/21/2000
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Implantable glucose sensor | ||
Patent #
US 6,815,186 B2
Filed 01/28/2002
|
Current Assignee
Arbmetrics LLC
|
Original Assignee
Implanted Biosystems Incorporated
|
Implantable enzyme-based monitoring systems adapted for long term use | ||
Patent #
US 6,512,939 B1
Filed 06/27/2000
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 20030032874A1
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Subcutaneous glucose electrode | ||
Patent #
US 6,514,718 B2
Filed 11/29/2001
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Therasense Incorporated
|
Implantable enzyme-based monitoring system having improved longevity due to improved exterior surfaces | ||
Patent #
US 20030065254A1
Filed 10/31/2002
|
Current Assignee
Alfred E. Mann Foundation For Scientific Research
|
Original Assignee
Alfred E. Mann Foundation For Scientific Research
|
Microstructured bilateral sensor | ||
Patent #
US 6,551,496 B1
Filed 03/06/2001
|
Current Assignee
YSI Incorporated
|
Original Assignee
YSI Incorporated
|
Nanoporous silicone resins having low dielectric constants | ||
Patent #
US 6,541,107 B1
Filed 10/25/1999
|
Current Assignee
Dow Inc.
|
Original Assignee
Dow Inc.
|
Polar solvent compatible polyethersiloxane elastomers | ||
Patent #
US 6,545,085 B2
Filed 10/05/2001
|
Current Assignee
Citibank South Dakota NA
|
Original Assignee
General Electric Company
|
Analyte monitoring device and methods of use | ||
Patent #
US 6,565,509 B1
Filed 09/21/2000
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Therasense Incorporated
|
Device for signal processing for measurement of physiological analytes | ||
Patent #
US 6,595,919 B2
Filed 02/27/2001
|
Current Assignee
LifeScan IP Holdings LLC
|
Original Assignee
Cygnus Inc.
|
Formulation and manipulation of databases of analyte and associated values | ||
Patent #
US 6,633,772 B2
Filed 08/10/2001
|
Current Assignee
LifeScan IP Holdings LLC
|
Original Assignee
Cygnus Inc.
|
Implantable glucose sensor | ||
Patent #
US 6,343,225 B1
Filed 09/14/1999
|
Current Assignee
Arbmetrics LLC
|
Original Assignee
Implanted Biosystems Incorporated
|
RETRIEVABLE BIOARTIFICIAL IMPLANTS HAVING DIMENSIONS ALLOWING RAPID DIFFUSION OF OXYGEN AND RAPID BIOLOGICAL RESPONSE TO PHYSIOLOGICAL CHANGE, PROCESSES FOR THEIR MANUFACTURE, AND METHODS FOR THEIR USE | ||
Patent #
US 6,372,244 B1
Filed 08/25/2000
|
Current Assignee
Islet Sheet Medical LLC
|
Original Assignee
ISLET SHEET MEDICAL INC.
|
Implanted sensor processing system and method for processing implanted sensor output | ||
Patent #
US 6,400,974 B1
Filed 06/29/2000
|
Current Assignee
Senseonics Incorporated
|
Original Assignee
Sensors For Medicine and Science Incorporated
|
Enzyme electrode sensor and manufacturing method thereof | ||
Patent #
US 6,413,396 B1
Filed 02/04/2000
|
Current Assignee
Electronics and Telecommunications Research Institute
|
Original Assignee
Electronics and Telecommunications Research Institute
|
Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces | ||
Patent #
US 6,477,395 B2
Filed 09/14/1999
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Prostheses for plastic reconstruction with improved hydrophilicity properties, and method for obtaining them | ||
Patent #
US 20020193885A1
Filed 03/25/2002
|
Current Assignee
Association Pour Les Transferts De Technologies Du Mans
|
Original Assignee
ASSOC. POUR LES TRANSFERTS DE TECHNOLOGIES DU MANS
|
Device for monitoring changes in analyte concentration | ||
Patent #
US 6,212,416 B1
Filed 05/22/1998
|
Current Assignee
LEGACY GOOD SAMARITAN HOSPITAL AND MEDICAL CENTER
|
Original Assignee
Good Samaritan Hospital Medical Center
|
Implantable device containing GDNF secreting cells for treating nerve damage and methods of use | ||
Patent #
US 6,015,572 A
Filed 05/30/1995
|
Current Assignee
Amgen Inc.
|
Original Assignee
Amgen Inc.
|
Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products | ||
Patent #
US 6,083,523 A
Filed 09/04/1998
|
Current Assignee
Neurotech S.A.
|
Original Assignee
Brown University
|
Optical oxidative enzyme-based sensors | ||
Patent #
US 6,107,083 A
Filed 08/21/1998
|
Current Assignee
Siemens Healthcare Diagnostics Incorporated
|
Original Assignee
Bayer Corporation
|
Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces | ||
Patent #
US 6,119,028 A
Filed 10/20/1997
|
Current Assignee
Alfred E. Mann Foundation For Scientific Research
|
Original Assignee
Alfred E. Mann Foundation For Scientific Research
|
Implantable sensor and system for measurement and control of blood constituent levels | ||
Patent #
US 6,122,536 A
Filed 06/23/1998
|
Current Assignee
Animas Corporation
|
Original Assignee
Animas Corporation
|
Chemical signal-impermeable mask | ||
Patent #
US 6,141,573 A
Filed 08/04/1998
|
Current Assignee
Animas Technologies LLC
|
Original Assignee
Cygnus Inc.
|
Polyurethane/polyurea compositions containing silicone for biosensor membranes | ||
Patent #
US 5,882,494 A
Filed 08/28/1995
|
Current Assignee
Minimed Inc.
|
Original Assignee
Minimed Inc.
|
Diffusional implantable delivery system | ||
Patent #
US 5,972,369 A
Filed 03/30/1998
|
Current Assignee
ALZA Corporation
|
Original Assignee
ALZA Corporation
|
Implantable system for cell growth control | ||
Patent #
US 5,964,745 A
Filed 03/18/1996
|
Current Assignee
US MED
|
Original Assignee
US MED
|
Glucose sensor | ||
Patent #
US 5,964,993 A
Filed 12/19/1996
|
Current Assignee
Tenax Therapeutics Inc.
|
Original Assignee
Implanted Biosystems Incorporated
|
Method for increasing the service life of an implantable sensor | ||
Patent #
US 5,985,129 A
Filed 04/28/1992
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Device and method for determining analyte levels | ||
Patent #
US 6,001,067 A
Filed 03/04/1997
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Markwell Medical Institute Inc.
|
Three-layered membrane for use in an electrochemical sensor system | ||
Patent #
US 5,773,270 A
Filed 05/17/1994
|
Current Assignee
Chiron Corporation
|
Original Assignee
Chiron Corporation
|
Method for producing improved sensor | ||
Patent #
US 5,783,054 A
Filed 04/09/1997
|
Current Assignee
BIOSENSOR ENTERPRISES LLC
|
Original Assignee
University of Sydney, Australian Membrane and Biotechnology Research Institute
|
Silicon-containing biocompatible membranes | ||
Patent #
US 5,777,060 A
Filed 09/26/1996
|
Current Assignee
Minimed Inc.
|
Original Assignee
Minimed Inc.
|
Biosensor | ||
Patent #
US 5,795,774 A
Filed 07/10/1997
|
Current Assignee
NEC Corporation
|
Original Assignee
NEC Corporation
|
Electrode assembly for assaying glucose | ||
Patent #
US 5,804,048 A
Filed 08/15/1996
|
Current Assignee
Segars California Partners LP
|
Original Assignee
VIA MEDICAL CORPORATION
|
Thickening silicones with elastomeric silicone polyethers | ||
Patent #
US 5,811,487 A
Filed 12/16/1996
|
Current Assignee
Dow Inc.
|
Original Assignee
Dow Inc.
|
Implantable non-invasive rate-adjustable pump | ||
Patent #
US 5,820,589 A
Filed 04/30/1996
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Breathable liquid elimination analysis | ||
Patent #
US 5,590,651 A
Filed 01/17/1995
|
Current Assignee
Temple University of The Commonwealth System of Higher Education
|
Original Assignee
Temple University of The Commonwealth System of Higher Education
|
Optical glucose sensor | ||
Patent #
US 5,605,152 A
Filed 07/18/1994
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Minimed Inc.
|
Microbiosensor used in-situ | ||
Patent #
US 5,611,900 A
Filed 07/20/1995
|
Current Assignee
Michigan State University
|
Original Assignee
Michigan State University
|
Electrochemical sensors | ||
Patent #
US 5,494,562 A
Filed 06/27/1994
|
Current Assignee
Siemens Healthcare Diagnostics Incorporated
|
Original Assignee
CIBA Vision Corporation
|
Surface-modifying endgroups for biomedical polymers | ||
Patent #
US 5,589,563 A
Filed 04/01/1994
|
Current Assignee
Polymer Technology Group Inc.
|
Original Assignee
Polymer Technology Group Inc.
|
Enhancing the hydrophilicity of silicone polymers | ||
Patent #
US 5,397,848 A
Filed 05/21/1993
|
Current Assignee
Abbott Medical Optics Incorporated
|
Original Assignee
Allergan Inc. Canada
|
Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range | ||
Patent #
US 5,428,123 A
Filed 04/23/1993
|
Current Assignee
Polymer Technology Group Inc.
|
Original Assignee
Polymer Technology Group Inc.
|
Implantable catheter with electrical pulse nerve stimulators and drug delivery system | ||
Patent #
US 5,458,631 A
Filed 03/22/1994
|
Current Assignee
Ravi Xavier
|
Original Assignee
Ravi Xavier
|
Acrylic copolymer membranes for biosensors | ||
Patent #
US 5,476,094 A
Filed 11/15/1993
|
Current Assignee
Disetronic Licensing Ag
|
Original Assignee
Eli Lilly and Company
|
Hydrophilic polyurethane membranes for electrochemical glucose sensors | ||
Patent #
US 5,322,063 A
Filed 10/04/1991
|
Current Assignee
Disetronic Licensing Ag
|
Original Assignee
Eli Lilly and Company
|
Polysiloxane-polylactone block copolymers | ||
Patent #
US 5,235,003 A
Filed 08/31/1990
|
Current Assignee
TC1 LLC
|
Original Assignee
Thoratec Laboratories Corp.
|
Noninvasive blood glucose measuring device | ||
Patent #
US 5,140,985 A
Filed 10/21/1991
|
Current Assignee
Jon M. Schroeder, Joseph F. Long
|
Original Assignee
Jon M. Schroeder, Joseph F. Long
|
Enzyme electrodes and improvements in the manufacture thereof | ||
Patent #
US 5,160,418 A
Filed 07/18/1989
|
Current Assignee
CAMBRIDGE LIFE SCIENCES PLC
|
Original Assignee
CAMBRIDGE LIFE SCIENCES PLC
|
Biological fluid measuring device | ||
Patent #
US 4,994,167 A
Filed 07/07/1988
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Markwell Medical Institute Inc.
|
Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor | ||
Patent #
US 5,030,333 A
Filed 10/14/1986
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Two-dimensional diffusion glucose substrate sensing electrode | ||
Patent #
US 4,890,620 A
Filed 02/17/1988
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Polysiloxane-polylactone block copolymers | ||
Patent #
US 4,963,595 A
Filed 12/22/1988
|
Current Assignee
TC1 LLC
|
Original Assignee
Thoratec Laboratories Corp.
|
Immobilized enzyme electrodes | ||
Patent #
US 4,970,145 A
Filed 01/20/1988
|
Current Assignee
CAMBRIDGE LIFE SCIENCES PLC A CORP. OF GREAT BRITAIN
|
Original Assignee
CAMBRIDGE LIFE SCIENCES PLC
|
Block-graft copolymer | ||
Patent #
US 4,803,243 A
Filed 03/25/1987
|
Current Assignee
Shin-Etsu Chemical Company Limited
|
Original Assignee
Shin-Etsu Chemical Company Limited
|
Segmented polyether polyurethane | ||
Patent #
US 4,849,458 A
Filed 06/17/1988
|
Current Assignee
Innovative Technologies Incorporated
|
Original Assignee
Matrix Medical LLC
|
Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming | ||
Patent #
US 4,861,830 A
Filed 06/22/1987
|
Current Assignee
TC1 LLC
|
Original Assignee
Th. Goldschmidt AG
|
Implantable gas-containing biosensor and method for measuring an analyte such as glucose | ||
Patent #
US 4,721,677 A
Filed 05/07/1987
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Method and membrane applicable to implantable sensor | ||
Patent #
US 4,650,547 A
Filed 12/20/1985
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Implantable gas-containing biosensor and method for measuring an analyte such as glucose | ||
Patent #
US 4,680,268 A
Filed 09/18/1985
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Test device, method of manufacturing same and method of determining a component in a sample | ||
Patent #
US 4,689,309 A
Filed 09/30/1985
|
Current Assignee
Miles Laboratories Inc.
|
Original Assignee
Miles Laboratories Inc.
|
Polycarbonate-polyether-copolymer membrane | ||
Patent #
US 4,686,044 A
Filed 12/09/1985
|
Current Assignee
Akzo Nobel N.V.
|
Original Assignee
Akzo Nobel N.V.
|
Complete glucose monitoring system with an implantable, telemetered sensor module | ||
Patent #
US 4,703,756 A
Filed 05/06/1986
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Implantable glucose sensor | ||
Patent #
US 4,431,004 A
Filed 10/27/1981
|
Current Assignee
Ennis C. Layne, Samuel P. Bessman, Lyell J. Thomas
|
Original Assignee
Ennis C. Layne, Samuel P. Bessman, Lyell J. Thomas
|
Method and membrane applicable to implantable sensor | ||
Patent #
US 4,484,987 A
Filed 05/19/1983
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Enzyme electrode membrane | ||
Patent #
US 4,415,666 A
Filed 11/05/1981
|
Current Assignee
Miles Laboratories Inc.
|
Original Assignee
Miles Laboratories Inc.
|
Multilayer enzyme electrode membrane | ||
Patent #
US 4,418,148 A
Filed 11/05/1981
|
Current Assignee
Miles Laboratories Inc.
|
Original Assignee
Miles Laboratories Inc.
|
Membrane for enzyme electrodes | ||
Patent #
US 4,073,713 A
Filed 07/26/1976
|
Current Assignee
The Yellow Springs Instrument Company Inc.
|
Original Assignee
THE YELLOW SPRINGS INSTRUMENT COMPANY INC.
|
Polarographic analysis of cholesterol and other macromolecular substances | ||
Patent #
US 4,040,908 A
Filed 03/12/1976
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Membrane for enzyme electrodes | ||
Patent #
US 3,979,274 A
Filed 09/24/1975
|
Current Assignee
The Yellow Springs Instrument Company Inc.
|
Original Assignee
THE YELLOW SPRINGS INSTRUMENT COMPANY INC.
|
21 Claims
-
1. An electrochemical sensor for determining a presence or a concentration of an analyte in a fluid, the sensor comprising:
-
a membrane system comprising an enzyme domain comprising an enzyme that reacts with the analyte in the fluid as it passes through the enzyme domain; and
a working electrode comprising a conductive material, wherein the working electrode is configured to measure a product of a reaction of the enzyme with the analyte, wherein the membrane system comprises a polymer material with a high oxygen solubility. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. An analyte sensing device configured for implantation into a tissue of a host, the device comprising:
-
an oxygen-utilizing source;
a membrane system configured to provide at least one function selected from the group consisting of;
protection of the device from a biological environment;
diffusion resistance of an analyte;
a catalyst for enabling an enzymatic reaction; and
limitation of interfering species;
wherein the membrane system comprises a polymer material with a high oxygen solubility, wherein the membrane system is adjacent to the oxygen-utilizing source. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21)
-
1 Specification
This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/490,009, filed Jul. 25, 2003, the contents of which are hereby incorporated by reference in their entirety.
The present invention relates generally to systems and methods for increasing oxygen availability in implantable devices.
Electrochemical sensors are useful in chemistry and medicine to determine the presence or concentration of a biological analyte. Such sensors are useful, for example, to monitor glucose in diabetic patients and lactate during critical care events.
Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which causes an array of physiological derangements (kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) is induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically utilizes uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a diabetic normally only measures his or her glucose level two to four times per day. Unfortunately, these time intervals are spread so far apart that the diabetic likely finds out too late, sometimes incurring dangerous side effects, of a hyperglycemic or hypoglycemic condition. In fact, it is not only unlikely that a diabetic will take a timely SMBG value, but additionally the diabetic will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods.
Consequently, a variety of transdermal and implantable electrochemical sensors are being developed for continuously detecting and/or quantifying blood glucose values. Many implantable glucose sensors suffer from complications within the body and provide only short-term or less-than-accurate sensing of blood glucose. Similarly, transdermal sensors have problems in accurately sensing and reporting back glucose values continuously over extended periods of time. Some efforts have been made to obtain blood glucose data from implantable devices and retrospectively determine blood glucose trends for analysis; however these efforts do not aid the diabetic in determining real-time blood glucose information. Some efforts have also been made to obtain blood glucose data from transdermal devices for prospective data analysis, however similar problems have been observed.
Sensors that can provide. accurate, real-time information under ischemic conditions are therefore desirable.
Accordingly, in a first embodiment, an electrochemical sensor for determining a presence or a concentration of an analyte in a fluid is provided, the sensor including a membrane system including an enzyme domain including an enzyme that reacts with the analyte in the fluid as it passes through the enzyme domain; and a working electrode including a conductive material, wherein the working electrode is configured to measure a product of a reaction of the enzyme with the analyte, wherein the membrane system includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the enzyme domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the polymer material is selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes a resistance domain configured to restrict a flow of the analyte therethrough, wherein the resistance domain is located more distal to the working electrode than the enzyme domain, and wherein the resistance domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the resistance domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes a cell impermeable domain that is substantially impermeable to cells, wherein the cell impermeable domain is located more distal to the working electrode than the enzyme domain, and wherein the cell impermeable domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the cell impermeable domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes a cell disruptive domain that includes a substantially porous structure, wherein the cell disruptive domain is located more distal to the working electrode than the enzyme domain, and wherein the cell disruptive domain includes a polymer material with high oxygen solubility.
In an aspect of the first embodiment, the cell impermeable domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes an interference domain configured to limit or block interfering species, wherein the interference domain is located more proximal to the working electrode than the enzyme domain, and wherein the interference domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the interference domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes an electrolyte domain configured to provide hydrophilicity at the working electrode, wherein the electrolyte domain is located more proximal to the working electrode than the enzyme domain, and wherein the electrolyte domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the electrolyte domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In a second embodiment, an analyte sensing device configured for implantation into a tissue of a host is provided, the device including an oxygen-utilizing source; a membrane system configured to provide at least one function selected from the group consisting of protection of the device from a biological environment; diffusion resistance of an analyte; a catalyst for enabling an enzymatic reaction; and limitation of interfering species; wherein the membrane system includes a polymer material with a high oxygen solubility, wherein the membrane system is adjacent to the oxygen-utilizing source.
In an aspect of the second embodiment, the oxygen-utilizing source includes an enzyme.
In an aspect of the second embodiment, the membrane system includes the polymer material with the high oxygen solubility, wherein the polymer material is substantially continuously situated between the enzyme and the tissue.
In an aspect of the second embodiment, the oxygen-utilizing source includes an electroactive surface.
In an aspect of the second embodiment, the membrane system includes the polymer material with the high oxygen solubility, wherein the polymer material is substantially continuously situated between the electroactive surface and the tissue.
In an aspect of the second embodiment, the oxygen-utilizing source includes cells.
In an aspect of the second embodiment, the membrane system includes the polymer material with the high oxygen solubility, wherein the polymer material is substantially continuously situated between the cells and the tissue.
In an aspect of the second embodiment, the polymer material is selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.
Definitions
In order to facilitate an understanding of the preferred embodiments, a number of terms are defined below.
The term “analyte” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensing regions, devices, and methods is glucose. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcamitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky'"'"'s disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid or endogenous, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body or exogenous, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
The terms “operable connection,” “operably connected,” and “operably linked” as used herein are broad terms and are used in their ordinary sense, including, without limitation, one or more components linked to another component(s) in a manner that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of analyte in a sample and convert that information into a signal; the signal can then be transmitted to a circuit. In this case, the electrode is “operably linked” to the electronic circuitry.
The term “host” as used herein is a broad term and is used in its ordinary sense, including, without limitation, mammals, particularly humans.
The terms “electrochemically reactive surface” and “electroactive surface” as used herein are broad terms and are used in their ordinary sense, including, without limitation, the surface of an electrode where an electrochemical reaction takes place. As one example, a working electrode measures hydrogen peroxide produced by the enzyme catalyzed reaction of the analyte being detected reacts creating an electric current (for example, detection of glucose analyte utilizing glucose oxidase produces H2O2 as a by product, H2O2 reacts with the surface of the working electrode producing two protons (2H+), two electrons (2e−) and one molecule of oxygen (O2) which produces the electronic current being detected). In the case of the counter electrode, a reducible species, for example, O2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
The term “sensing region” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the region of a monitoring device responsible for the detection of a particular analyte. The sensing region generally comprises a non-conductive body, a working electrode, a reference electrode, and/or a counter electrode (optional) passing through and secured within the body forming electrochemically reactive surfaces on the body, an electronic connective means at another location on the body, and a multi-domain membrane affixed to the body and covering the electrochemically reactive surface.
The terms “raw data stream” and “data stream,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, an analog or digital signal directly related to the measured glucose concentration from the glucose sensor. In one example, the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of a glucose concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
The term “counts,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a unit of measurement of a digital signal. In one example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode. In another example, counter electrode voltage measured in counts is directly related to a voltage.
The term “electrical potential,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the electrical potential difference between two points in a circuit which is the cause of the flow of a current.
The term “ischemia,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, local and temporary deficiency of blood supply due to obstruction of circulation to a part (for example, sensor). Ischemia can be caused by mechanical obstruction (for example, arterial narrowing or disruption) of the blood supply, for example.
The term “system noise,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, unwanted electronic or diffusion-related noise which can include Gaussian, motion-related, flicker, kinetic, or other white noise, for example.
The terms “signal artifacts” and “transient non-glucose related signal artifacts,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, signal noise that is caused by substantially non-glucose reaction rate-limiting phenomena, such as ischemia, pH changes, temperature changes, pressure, and stress, for example. Signal artifacts, as described herein, are typically transient and are characterized by higher amplitude than system noise.
The terms “low noise,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, noise that substantially decreases signal amplitude.
The terms “high noise” and “high spikes,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, noise that substantially increases signal amplitude.
The term “silicone composition” as used herein is a broad term and is used in its ordinary sense, including, without limitation, a composition of matter that comprises polymers having at least silicon and oxygen atoms in the backbone.
The phrase “distal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell disruptive domain is positioned farther from the sensor, then that domain is distal to the sensor.
The phrase “proximal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell impermeable domain is positioned nearer to the sensor, then that domain is proximal to the sensor.
The terms “interferants” and “interfering species,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In an electrochemical sensor, interfering species can include compounds with an oxidation potential that overlaps with that of the analyte to be measured.
As employed herein, the following abbreviations apply: Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); μL (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade).
Overview
Membrane systems of the preferred embodiments are suitable for use with implantable devices in contact with a biological fluid. For example, the membrane systems can be utilized with implantable devices such as devices for monitoring and determining analyte levels in a biological fluid, for example, glucose levels for individuals having diabetes. In some embodiments, the analyte-measuring device is a continuous device. Alternatively, the device can analyze a plurality of intermittent biological samples. The analyte-measuring device can use any method of analyte-measurement, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like.
Although some of the description that follows is directed at glucose-measuring devices, including the described membrane systems and methods for their use, these membrane systems are not limited to use in devices that measure or monitor glucose. These membrane systems are suitable for use in a variety of devices, including, for example, those that detect and quantify other analytes present in biological fluids (including, but not limited to, cholesterol, amino acids, alcohol, galactose, and lactate), cell transplantation devices (see, for example, U.S. Pat. Nos. 6,015,572, 5,964,745, and 6,083,523), drug delivery devices (see, for example, U.S. Pat. Nos. 5,458,631, 5,820,589, and 5,972,369), and the like. Preferably, implantable devices that include the membrane systems of the preferred embodiments are implanted in soft tissue, for example, abdominal, subcutaneous, and peritoneal tissues, the brain, the intramedullary space, and other suitable organs or body tissues.
In addition to the glucose-measuring device described below, the membrane systems of the preferred embodiments can be employed with a variety of known glucose measuring-devices. In some embodiments, the electrode system can be used with any of a variety of known in vivo analyte sensors or monitors, such as U.S. Pat. No. 6,001,067 to Shults et al.; U.S. Pat. No. 6,702,857 to Brauker et al.; U.S. Pat. No. 6,212,416 to Ward et al.; U.S. Pat. No. 6,119,028 to Schulman et al.; U.S. Pat. No. 6,400,974 to Lesho; U.S. Pat. No. 6,595,919 to Berner et al.; U.S. Pat. No. 6,141,573 to Kurnik et al.; U.S. Pat. No. 6,122,536 to Sun et al.; European Patent Application EP 1153571 to Varall et al.; U.S. Pat. No. 6,512,939 to Colvin et al.; U.S. Pat. No. 5,605,152 to Slate et al.; U.S. Pat. No. 4,431,004 to Bessman et al.; U.S. Pat. No. 4,703,756 to Gough et al.; U.S. Pat. No. 6,514,718 to Heller et al.; U.S. Pat. No. to 5,985,129 to Gough et al.; WO Patent Application Publication No. 04/021877 to Caduff; U.S. Pat. No. 5,494,562 to Maley et al.; U.S. Pat. No. 6,120,676 to Heller et al.; and U.S. Pat. No. 6,542,765 to Guy et al, each of which are incorporated in there entirety herein by reference. In general, it is understood that the disclosed embodiments are applicable to a variety of continuous glucose measuring device configurations.
In this embodiment, the electrode system 16 is operably connected to the sensor electronics (
The membrane system 18 of the preferred embodiments, which are described in more detail below with reference to
In some embodiments, the electrode system 16, which is located on or within the sensing region 14, is comprised of at least a working and a reference electrode with an insulating material disposed therebetween. In some alternative embodiments, additional electrodes can be included within the electrode system, for example, a three-electrode system (working, reference, and counter electrodes) and/or including an additional working electrode (which can be used to generate oxygen, measure an additional analyte, or can be configured as a baseline subtracting electrode, for example).
In the exemplary embodiment of
GOX+Glucose+O2→Gluconate+H2O2+reduced GOX
The change in H2O2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H2O2. Oxidation of H2O2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H2O2, or other reducible species at the counter electrode. The H2O2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H+), two electrons (2e−), and one oxygen molecule (O2). In such embodiments, because the counter electrode utilizes oxygen as an electron acceptor, the most likely reducible species for this system are oxygen or enzyme generated peroxide. There are two main pathways by which oxygen can be consumed at the counter electrode. These pathways include a four-electron pathway to produce hydroxide and a two-electron pathway to produce hydrogen peroxide. In addition to the counter electrode, oxygen is further consumed by the reduced glucose oxidase within the enzyme domain. Therefore, due to the oxygen consumption by both the enzyme and the counter electrode, there is a net consumption of oxygen within the electrode system. Theoretically, in the domain of the working electrode there is significantly less net loss of oxygen than in the region of the counter electrode. In addition, there is a close correlation between the ability of the counter electrode to maintain current balance and sensor function.
In general, in electrochemical sensors wherein an enzymatic reaction depends on oxygen as a co-reactant, depressed function or inaccuracy can be experienced in low oxygen environments, for example in vivo. Subcutaneously implanted devices are especially susceptible to transient ischemia that can compromise device function; for example, because of the enzymatic reaction required for an implantable amperometric glucose sensor, oxygen must be in excess over glucose in order for the sensor to effectively function as a glucose sensor. If glucose becomes in excess, the sensor turns into an oxygen sensitive device. In vivo, glucose concentration can vary from about one hundred times or more that of the oxygen concentration. Consequently, oxygen becomes a limiting reactant in the electrochemical reaction and when insufficient oxygen is provided to the sensor, the sensor is unable to accurately measure glucose concentration. Those skilled in the art interpret oxygen limitations resulting in depressed function or inaccuracy as a problem of availability of oxygen to the enzyme and/or counter electrode. Oxygen limitations can also be seen during periods of transient ischemia that occur, for example, under certain postures or when the region around the implanted sensor is compressed so that blood is forced out of the capillaries. Such ischemic periods observed in implanted sensors can last for many minutes or even an hour or longer.
A microprocessor 22 is the central control unit that houses EEPROM 23 and SRAM 24, and controls the processing of the sensor electronics. The alternative embodiments can utilize a computer system other than a microprocessor to process data as described herein. In some alternative embodiments, an application-specific integrated circuit (ASIC) can be used for some or all the sensor'"'"'s central processing. EEPROM 23 provides semi-permanent storage of data, storing data such as sensor ID and programming to process data signals (for example, programming for data smoothing such as described elsewhere herein). SRAM 24 is used for the system'"'"'s cache memory, for example for temporarily storing recent sensor data.
The battery 25 is operatively connected to the microprocessor 22 and provides the power for the sensor. In one embodiment, the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery can be used. In some embodiments, a plurality of batteries can be used to power the system. Quartz Crystal 26 is operatively connected to the microprocessor 22 and maintains system time for the computer system.
The RF Transceiver 27 is operably connected to the microprocessor 22 and transmits the sensor data from the sensor to a receiver. Although a RF transceiver is shown here, some other embodiments can include a wired rather than wireless connection to the receiver. In yet other embodiments, the sensor can be transcutaneously connected via an inductive coupling, for example. The quartz crystal 28 provides the system time for synchronizing the data transmissions from the RF transceiver. The transceiver 27 can be substituted with a transmitter in one embodiment.
Although FIGS. 1 to 2 and associated text illustrate and describe one exemplary embodiment of an implantable glucose sensor, the electrode system, electronics and its method of manufacture of the preferred embodiments described below can be implemented on any known electrochemical sensor, including those described in co-pending U.S. patent application Ser. No. 10/838,912 filed May 3, 2004 and entitled, “IMPLANTABLE ANALYTE SENSOR”; U.S. patent application Ser. No. 10/789,359 filed Feb. 26, 2004 and entitled, “INTEGRATED DELIVERY DEVICE FOR A CONTINUOUS GLUCOSE SENSOR”; “OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR”; U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”, the contents of each of which are hereby incorporated by reference in their entireties.
The raw data stream 30 includes substantially smooth sensor output in some portions, however other portions exhibit erroneous or transient non-glucose related signal artifacts 32. Particularly, referring to the signal artifacts 32, it is believed that effects of local ischemia on prior art electrochemical sensors creates erroneous (non-glucose) signal values due to oxygen deficiencies either at the enzyme within the membrane system and/or at the counter electrode on the electrode surface.
In one situation, when oxygen is deficient relative to the amount of glucose, the enzymatic reaction is limited by oxygen rather than glucose. Thus, the output signal is indicative of the oxygen concentration rather than the glucose concentration, producing erroneous signals. Additionally, when an enzymatic reaction is rate-limited by oxygen, glucose is expected to build up in the membrane because it is not completely catabolized during the oxygen deficit. When oxygen is again in excess, there is also excess glucose due to the transient oxygen deficit. The enzyme rate then speeds up for a short period until the excess glucose is catabolized, resulting in spikes of non-glucose related increased sensor output. Accordingly, because excess oxygen (relative to glucose) is necessary for proper sensor function, transient ischemia can result in a loss of signal gain in the sensor data.
In another situation, oxygen deficiency can be seen at the counter electrode when insufficient oxygen is available for reduction, which thus affects the counter electrode in that it is unable to balance the current coming from the working electrode. When insufficient oxygen is available for the counter electrode, the counter electrode can be driven in its electrochemical search for electrons all the way to its most negative value, which can be ground, or 0.0 V, which causes the reference to shift, reducing the bias voltage such as is described in more detail below. In other words, a common result of ischemia is seen as a drop off in sensor current as a function of glucose concentration (for example, lower sensitivity). This occurs because the working electrode no longer oxidizes all of the H2O2 arriving at its surface because of the reduced bias. In some extreme circumstances, an increase in glucose can produce no increase in current or even a decrease in current.
In some situations, transient ischemia can occur at high glucose levels, wherein oxygen can become limiting to the enzymatic reaction, resulting in a non-glucose dependent downward trend in the data. In some situations, certain movements or postures taken by the patient can cause transient signal artifacts as blood is squeezed out of the capillaries, resulting in local ischemia, and causing non-glucose dependent signal artifacts. In some situations, oxygen can also become transiently limited due to contracture of tissues around the sensor interface. This is similar to the blanching of skin that can be observed when one puts pressure on it. Under such pressure, transient ischemia can occur in both the epidermis and subcutaneous tissue. Transient ischemia is common and well tolerated by subcutaneous tissue. However, such ischemic periods can cause an oxygen deficit in implanted devices that can last for many minutes or even an hour or longer.
Although some examples of the effects of transient ischemia on a prior art glucose sensor are described above, similar effects can be seen with analyte sensors that use alternative catalysts to detect other analytes, for example, amino acids (amino acid oxidase), alcohol (alcohol oxidase), galactose (galactose oxidase), lactate (lactate oxidase), and cholesterol (cholesterol oxidase), or the like.
Membrane Systems of the Preferred Embodiments
In order to overcome the effects of transient ischemia, the membrane systems 18 of the preferred embodiments include materials with high oxygen solubility. These materials increase the local amount of oxygen to aid in compensating for local oxygen deficits during ischemic conditions. As a result, the membrane systems of the preferred embodiments enable analyte sensors and other devices such as cell transplantation devices to function in the subcutaneous space even during local transient ischemia.
The phrases “high oxygen solubility” and “high oxygen soluble” as used herein are broad phrases and are used in their ordinary sense, including, without limitation, a domain or material property that includes higher oxygen solubility than aqueous media so that it concentrates oxygen from the biological fluid surrounding the membrane system. In some preferred embodiments, a high oxygen solubility polymer has at least about 3× higher oxygen solubility than aqueous media, more preferably at least about 4×, 5×, or 6× higher oxygen solubility than aqueous media, and most preferably at least about 7×, 8×, 9×, 10× or more higher oxygen solubility than aqueous media. In one embodiment, high oxygen solubility is defined as having higher oxygen solubility than at least one of a hydrocarbonaceous polymer and an oxyhydrocarbon polymer (a hydrocarbonaceous polymer is a polymeric material consisting of carbon and hydrogen atoms and an oxyhydrocarbonaceous polymer is a polymeric material consisting of carbon, hydrogen, and oxygen atoms). Oxygen solubility can be measured using any known technique, for example by removing the oxygen from the polymer (namely, solution) via at least three Freeze-Pump-Thaw cycles and then measuring the resultant oxygen (for example, using a manometer).
Oxygen permeability (Dk) is calculated as diffusion multiplied by solubility. Oxygen Permeability is conveniently reported in units of Barrers (1 Barrer=10−10 cm3 O2 (STP) cm/cm2s cmHg). Insulating materials of preferred embodiments that have a high oxygen permeability typically have an oxygen permeability of from about 1 Barrer or less to about 1000 Barrers or more, preferably from about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 Barrers to about 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 950 Barrers.
In one exemplary embodiment, the properties of silicone (and/or silicone compositions) inherently enable materials formed from silicone to act as a high oxygen solubility domain. Utilization of a high oxygen soluble material in an electrochemical sensor is advantageous because it is believed to dynamically retain high oxygen availability to oxygen-utilizing sources (for example, an enzyme and/or a counter electrode of an electrochemical cell).
As described below with reference to
The membrane systems of preferred embodiments are constructed of two or more domains. The multi-domain membrane can be formed from one or more distinct layers and can comprise the same or different materials. The term “domain” is a broad term and is used in its ordinary sense, including, without limitation, a single homogeneous layer or region that incorporates the combined functions one or more domains, or a plurality of layers or regions that each provide one or more of the functions of each of the various domains.
In some embodiments, the membrane system is formed as a homogeneous membrane, namely, a membrane having substantially uniform characteristics from one side of the membrane to the other. However, a membrane can have heterogeneous structural domains, for example, domains resulting from the use of block copolymers (for example, polymers in which different blocks of identical monomer units alternate with each other), but can be defined as homogeneous overall in that each of the above-described domains functions by the preferential diffusion of some substance through the homogeneous membrane.
In the preferred embodiments, one or more of the above-described domains are formed from high oxygen solubility material. Utilization of high oxygen solubility material is advantageous because it is believed to dynamically retain a higher amount of oxygen, which maintains higher oxygen availability to selected locations (for example, the enzyme and/or counter electrode). In some embodiments, the high oxygen soluble material includes silicones, fluorocarbons, perfluorocarbons, or the like. In one embodiment, one or more domains is/are formed from a silicone composition that allows the transport of glucose other such water-soluble molecules (for example, drugs), such as are described in more detail with reference to co-pending U.S. application Ser. No. 10/685,636 filed Oct. 28, 2003 and entitled, “SILICONE COMPOSITION FOR MEMBRANE SYSTEM,” the contents of which are hereby incorporated by reference in their entireties.
Cell Disruptive Domain
The cell disruptive domain 40 is positioned most distal to the implantable device and is designed to support tissue ingrowth, to disrupt contractile forces typically found in a foreign body capsule, to encourage vascularity within the membrane, and/or to disrupt the formation of a barrier cell layer. In one embodiment, the cell disruptive domain 40 has an open-celled configuration with interconnected cavities and solid portions, wherein the distribution of the solid portion and cavities of the cell disruptive domain includes a substantially co-continuous solid domain and includes more than one cavity in three dimensions substantially throughout the entirety of the first domain. Cells can enter into the cavities; however they cannot travel through or wholly exist within the solid portions. The cavities allow most substances to pass through, including, for example, cells, and molecules. U.S. Pat. No. 6,702,857, filed Jul. 27, 2001, and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES” and U.S. patent application Ser. No. 10/647,065, filed Aug. 22, 2003, and entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES” describe membranes having a cell disruptive domain.
The cell disruptive domain 40 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the cell disruptive domain is formed from a silicone composition with a non-silicon containing hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In some alternative embodiments, the cell disruptive domain is formed from polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polytetrafluoroethylene, polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyurethanes, cellulosic polymers, polysulfones or block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers.
In preferred embodiments, the thickness of the cell disruptive domain is from about 10 or less, 20, 30, 40, 50, 60, 70, 80, or 90 microns to about 1500, 2000, 2500, or 3000 or more microns. In more preferred embodiments, the thickness of the cell disruptive domain is from about 100, 150, 200 or 250 microns to about 1000, 1100, 1200, 1300, or 1400 microns. In even more preferred embodiments, the thickness of the cell disruptive domain is from about 300, 350, 400, 450, 500, or 550 microns to about 500, 550, 600, 650, 700, 750, 800, 850, or 900 microns.
The cell disruptive domain is optional and can be omitted when using an implantable device that does not prefer tissue ingrowth, for example, a short-lived device (for example, less than one day to about a week) or one that delivers tissue response modifiers.
Cell Impermeable Domain
The cell impermeable domain 42 is positioned less distal to the implantable device than the cell disruptive domain, and can be resistant to cellular attachment, impermeable to cells, and/or is composed of a biostable material. When the cell impermeable domain is resistant to cellular attachment (for example, attachment by inflammatory cells, such as macrophages, which are therefore kept a sufficient distance from other domains, for example, the enzyme domain), hypochlorite and other oxidizing species are short-lived chemical species in vivo, and biodegradation does not occur. Additionally, the materials preferred for forming this domain are resistant to the effects of these oxidative species and have thus been termed biodurable. See, for example, U.S. Pat. No. 6,702,857, filed Jul. 27, 2001, and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES” and U.S. patent application Ser. No. 10/647,065, filed Aug. 22, 2003, and entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES.”
The cell impermeable domain 42 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the cell impermeable domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In some alternative embodiments, the cell impermeable domain is formed from copolymers or blends of copolymers with hydrophilic polymers such as polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate, polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene glycol, and block copolymers thereof, including, for example, di-block, tri-block, alternating, random and graft copolymers (block copolymers are discussed in U.S. Pat. Nos. 4,803,243 and 4,686,044).
In preferred embodiments, the thickness of the cell impermeable domain is from about 10 or 15 microns or less to about 125, 150, 175, or 200 microns or more. In more preferred embodiments, the thickness of the cell impermeable domain is from about 20, 25, 30, or 35 microns to about 65, 70, 75, 80, 85, 90, 95, or 100 microns. In even more preferred embodiments, the cell impermeable domain is from about 40 or 45 microns to about 50, 55, or 60 microns thick.
The cell disruptive domain 40 and cell impermeable domain 42 of the membrane system can be formed together as one unitary structure. Alternatively, the cell disruptive and cell impermeable domains 40, 42 of the membrane system can be formed as two layers mechanically or chemically bonded together.
Resistance Domain
The resistance domain 44 is situated more proximal to the implantable device relative to the cell disruptive domain. The resistance domain controls the flux of oxygen and other analytes (for example, glucose) to the underlying enzyme domain. As described in more detail elsewhere herein, there exists a molar excess of glucose relative to the amount of oxygen in blood; that is, for every free oxygen molecule in extracellular fluid, there are typically more than 100 glucose molecules present (see Updike et al., Diabetes Care 5:207-21(1982)). However, an immobilized enzyme-based sensor employing oxygen as cofactor is supplied with oxygen in non-rate-limiting excess in order to respond linearly to changes in glucose concentration, while not responding to changes in oxygen tension. More specifically, when a glucose-monitoring reaction is oxygen-limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane situated over the enzyme domain to control the flux of glucose and oxygen, a linear response to glucose levels can be obtained only up to about 40 mg/dL. However, in a clinical setting, a linear response to glucose levels is desirable up to at least about 500 mg/dL.
The resistance domain 44 includes a semipermeable membrane that controls the flux of oxygen and glucose to the underlying enzyme domain 46, preferably rendering oxygen in non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which is achieved without the resistance domain. In one embodiment, the resistance domain 44 exhibits an oxygen-to-glucose permeability ratio of approximately 200:1. As a result, one-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix (See Rhodes et al., Anal. Chem., 66:1520-1529 (1994)). In some embodiments, a lower ratio of oxygen-to-glucose can be sufficient to provide excess oxygen by using a high oxygen soluble domain (for example, a silicone material) to enhance the supply/transport of oxygen to the enzyme membrane and/or electroactive surfaces. By enhancing the oxygen supply through the use of a silicone composition, for example, glucose concentration can be less of a limiting factor. In other words, if more oxygen is supplied to the enzyme and/or electroactive surfaces, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess.
The resistance domain 44 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the resistance domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In some alternative embodiments, the resistance domain is from polyurethane, for example, a polyurethane urea/polyurethane-block-polyethylene glycol blend.
In some embodiments, the resistance domain 44 can be formed as a unitary structure with the cell impermeable domain 42; that is, the inherent properties of the resistance domain 44 can provide the functionality described with reference to the cell impermeable domain 42 such that the cell impermeable domain 42 is incorporated as a part of resistance domain 44. In these embodiments, the combined resistance domain/cell impermeable domain can be bonded to or formed as a skin on the cell disruptive domain 40 during a molding process such as described above. In another embodiment, the resistance domain 44 is formed as a distinct layer and chemically or mechanically bonded to the cell disruptive domain 40 (if applicable) or the cell impermeable domain 42 (when the resistance domain is distinct from the cell impermeable domain).
In preferred embodiments, the thickness of the resistance domain is from about 10 microns or less to about 200 microns or more. In more preferred embodiments, the thickness of the resistance domain is from about 15, 20, 25, 30, or 35 microns to about 65, 70, 75, 80, 85, 90, 95, or 100 microns. In more preferred embodiments, the thickness of the resistance domain is from about 40 or 45 microns to about 50, 55, or 60 microns.
Enzyme Domain
An immobilized enzyme domain 46 is situated less distal from the electrochemically reactive surfaces than the resistance domain 44. In one embodiment, the immobilized enzyme domain 46 comprises glucose oxidase. In other embodiments, the immobilized enzyme domain 46 can be impregnated with other oxidases, for example, galactose oxidase, cholesterol oxidase, amino acid oxidase, alcohol oxidase, lactate oxidase, or uricase. For example, for an enzyme-based electrochemical glucose sensor to perform well, the sensor'"'"'s response should neither be limited by enzyme activity nor cofactor concentration.
The enzyme domain 44 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the enzyme domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein.
In one preferred embodiment, high oxygen solubility within the enzyme domain can be achieved by using a polymer matrix to host the enzyme within the enzyme domain, which has a high solubility of oxygen. In one exemplary embodiment of fluorocarbon-based polymers, the solubility of oxygen within a perfluorocarbon-based polymer is 50-volume %. As a reference, the solubility of oxygen in water is approximately 2-volume %.
Utilization of a high oxygen solubility material for the enzyme domain is advantageous because the oxygen dissolves more readily within the domain and thereby acts as a high oxygen soluble domain optimizing oxygen availability to oxygen-utilizing sources (for example, the enzyme and/or counter electrode). When the resistance domain 44 and enzyme domain 46 both comprise a high oxygen soluble material, the chemical bond between the enzyme domain 46 and resistance domain 44 can be optimized, and the manufacturing made easy.
In preferred embodiments, the thickness of the enzyme domain is from about 1 micron or less to about 40, 50, 60, 70, 80, 90, or 100 microns or more. In more preferred embodiments, the thickness of the enzyme domain is between about 1, 2, 3, 4, or 5 microns and 13, 14, 15, 20, 25, or 30 microns. In even more preferred embodiments, the thickness of the enzyme domain is from about 6, 7, or 8 microns to about 9, 10, 11, or 12 microns.
Interference Domain
The interference domain 48 is situated less distal to the implantable device than the immobilized enzyme domain. Interferants are molecules or other species that are electro-reduced or electro-oxidized at the electrochemically reactive surfaces, either directly or via an electron transfer agent, to produce a false signal (for example, urate, ascorbate, or acetaminophen). In one embodiment, the interference domain 48 prevents the penetration of one or more interferants into the electrolyte phase around the electrochemically reactive surfaces. Preferably, this type of interference domain is much less permeable to one or more of the interferants than to the analyte.
In one embodiment, the interference domain 48 can include ionic components incorporated into a polymeric matrix to reduce the permeability of the interference domain to ionic interferants having the same charge as the ionic components. In another embodiment, the interference domain 48 includes a catalyst (for example, peroxidase) for catalyzing a reaction that removes interferants. U.S. Pat. Nos. 6,413,396 and 6,565,509 disclose methods and materials for eliminating interfering species; however in the preferred embodiments any suitable method or material can be employed.
In another embodiment, the interference domain 48 includes a thin membrane that is designed to limit diffusion of species, for example, those greater than 34 kD in molecular weight, for example. The interference domain permits analytes and other substances (for example, hydrogen peroxide) that are to be measured by the electrodes to pass through, while preventing passage of other substances, such as potentially interfering substances. In one embodiment, the interference domain 48 is constructed of polyurethane. In an alternative embodiment, the interference domain 48 comprises a high oxygen soluble polymer, such as described above.
In preferred embodiments, the thickness of the interference domain is from about 0.1 microns or less to about 10 microns or more. In more preferred embodiments, the thickness of the interference domain is between about 0.2, 0.3, 0.4, or 0.5 microns and about 5, 6, 7, 8, or 9 microns. In more preferred embodiments, the thickness of the interference domain is from about 0.6, 0.7, 0.8, 0.9, or 1 micron to about 2, 3, or 4 microns.
Electrolyte Domain
An electrolyte domain 50 is situated more proximal to the electrochemically reactive surfaces than the interference domain 48. To ensure the electrochemical reaction, the electrolyte domain 30 includes a semipermeable coating that maintains hydrophilicity at the electrochemically reactive surfaces of the sensor interface. The electrolyte domain 50 enhances the stability of the interference domain 48 by protecting and supporting the material that makes up the interference domain. The electrolyte domain also 50 assists in stabilizing the operation of the device by overcoming electrode start-up problems and drifting problems caused by inadequate electrolyte. The buffered electrolyte solution contained in the electrolyte domain also protects against pH-mediated damage that can result from the formation of a large pH gradient between the substantially hydrophobic interference domain and the electrodes due to the electrochemical activity of the electrodes. In some embodiments, the electrolyte domain may not be used, for example, when an interference domain is not provided.
In one embodiment, the electrolyte domain 50 includes a flexible, water-swellable, substantially solid gel-like film having a “dry film” thickness of from about 2.5 microns to about 12.5 microns, more preferably from about 3, 3.5, 4, 4.5, 5, or 5.5 to about 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, or 12 microns. “Dry film” thickness refers to the thickness of a cured film cast from a coating formulation onto the surface of the membrane by standard coating techniques.
In some embodiments, the electrolyte domain 50 is formed of a curable mixture of a urethane polymer and a hydrophilic polymer. Particularly preferred coatings are formed of a polyurethane polymer having anionic carboxylate functional groups and non-ionic hydrophilic polyether segments, which is crosslinked in the presence of polyvinylpyrrolidone and cured at a moderate temperature of about 50° C. In some preferred embodiments, the electrolyte domain 50 is formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like.
In one preferred embodiment, the electrolyte domain 50 is formed from a high oxygen soluble material, such as described above. In preferred embodiments, the thickness of the electrolyte domain is from about 1 micron or less to about 40, 50, 60, 70, 80, 90, or 100 microns or more. In more preferred embodiments, the thickness of the electrolyte domain is from about 2, 3, 4, or 5 microns to about 15, 20, 25, or 30 microns. In even more preferred embodiments, the thickness of the electrolyte domain is from about 6, 7, or 8 microns to about 9, 10, 11, or 12 microns.
Underlying the electrolyte domain is an electrolyte phase is a free-fluid phase including a solution containing at least one compound, typically a soluble chloride salt, which conducts electric current. In one embodiment wherein the membrane system is used with a glucose sensor such as is described herein, the electrolyte phase flows over the electrodes and is in contact with the electrolyte domain. The devices of the preferred embodiments contemplate the use of any suitable electrolyte solution, including standard, commercially available solutions. Generally, the electrolyte phase can have the same osmotic pressure or a lower osmotic pressure than the sample being analyzed. In preferred embodiments, the electrolyte phase comprises normal saline.
In various embodiments, any of these domains can be omitted, altered, substituted for, and/or incorporated together without departing from the spirit of the preferred embodiments. For example, a distinct cell impermeable domain may not exist. In such embodiments, other domains accomplish the function of the cell impermeable domain. As another example, the interference domain can be eliminated in certain embodiments wherein two-electrode differential measurements are employed to eliminate interference, for example, one electrode being sensitive to glucose and electrooxidizable interferants and the other only to interferants, such as is described in U.S. Pat. No. 6,514,718. In such embodiments, the interference domain can be omitted.
A variety of configurations are contemplated with the membrane systems of the preferred embodiments, however the exemplary configurations are not meant to be limiting and may be modified within the scope of the preferred embodiments. In one embodiment, the enzyme domain is formed from a material with a high oxygen solubility, which is believed to optimize oxygen availability to the enzyme immobilized therein. In another embodiment, all domains between the fluid supply (for example, interstitial fluid) and the enzyme (up to and including the enzyme domain) are formed from a material with a high oxygen solubility, which is believed to dynamically retain a substantially continuous path of high oxygen availability to the enzyme and/or electroactive surfaces during local ischemic periods. In yet another embodiment, all domains of a membrane system are formed from high oxygen soluble materials; in this way, the membrane system transports and/or maintains high oxygen availability substantially continuously across the membrane system, from the interstitial fluid to the implantable device surface, providing increased oxygen availability to the implantable device, for example electroactive surfaces thereon or transplanted cells located therein. While not wishing to be bound by theory, it is believed that maintaining high oxygen availability at the interface of the implantable device improves device performance even during transient ischemia and other low oxygen situations.
Reference is now made to
The upper dashed lines represent oxygen concentration in the fluid source (Cf) and oxygen concentration in the membrane system (Cm) at equilibrium (namely, without oxygen utilization) under normal conditions. However, when the membrane system 54a interfaces with an oxygen-utilizing source 56, oxygen concentration within the membrane system will be utilized. Accordingly, line 58a represents oxygen concentration under normal conditions decreasing at steady state as it passes through the membrane system 54a to the oxygen-utilizing source 56. While not wishing to be bound by theory, the oxygen concentration at the interface between the membrane system 54a and the oxygen-utilizing source 56 provides sufficient oxygen under normal conditions for oxygen-utilizing sources in vivo, such as enzymatic reactions, cellular processes, and electroactive surfaces.
Unfortunately, “normal conditions” do not always occur in vivo, for example during transient ischemic periods, such as described in more detail above with reference to
Referring to
The upper dashed lines represent oxygen concentration in the fluid source (Cf) and oxygen concentration in the membrane system (Cm) at equilibrium (namely, without oxygen utilization) under normal conditions. The membrane system of the preferred embodiments 54b is illustrated with a significantly higher oxygen concentration than the conventional membrane 54a. This higher oxygen concentration at equilibrium is attributed to higher oxygen solubility inherent in the properties of the membrane systems of the preferred embodiments as compared to conventional membrane materials. Line 58b represents oxygen concentration under normal conditions decreasing at steady state as it passes through the membrane system 54b to the oxygen-utilizing source 56. While not wishing to be bound by theory, the oxygen concentration at the interface between the membrane system 54b and the oxygen-utilizing source 56 is believe to provide sufficient oxygen under normal conditions for oxygen-utilizing sources in vivo, such as enzymatic reactions, cellular processes, and electroactive surfaces.
Such as described above, “normal conditions” do not always occur in vivo, for example during transient ischemic periods, wherein oxygen concentration is decreased below normal to a concentration as low as zero. Accordingly, line 60b represents oxygen concentration during ischemic conditions, wherein the oxygen concentration of the fluid source (Cf) is approximately half of its normal concentration. Because of the linear relationship between the fluid source oxygen concentration (Cf) and the membrane system oxygen concentration (Cm), the membrane system oxygen concentration, which is represented by a line 62b, is approximately half of its normal concentration. In contrast to the conventional membrane 62a illustrated in
Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in co-pending U.S. patent application Ser. No. 10/842,716, filed May 10, 2004 and entitled, “MEMBRANE SYSTEMS INCORPORATING BIOACTIVE AGENTS”; co-pending U.S. patent application Ser. No. 10/838,912 filed May 3, 2004 and entitled, “IMPLANTABLE ANALYTE SENSOR”; U.S. patent application Ser. No. 10/789,359 filed Feb. 26, 2004 and entitled, “INTEGRATED DELIVERY DEVICE FOR A CONTINUOUS GLUCOSE SENSOR”; U.S. application Ser. No. 10/685,636 filed Oct. 28, 2003 and entitled, “SILICONE COMPOSITION FOR MEMBRANE SYSTEM”; U.S. application Ser. No. 10/648,849 filed Aug. 22, 2003 and entitled, “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM”; U.S. application Ser. No. 10/646,333 filed Aug. 22, 2003 entitled, “OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR”; U.S. application Ser. No. 10/647,065 filed Aug. 22, 2003 entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. Pat. No. 6,702,857 entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 09/916,711 filed Jul. 27, 2001 and entitled “SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICE”; U.S. application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 10/153,356 filed May 22, 2002 and entitled “TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS”; U.S. application Ser. No. 09/489,588 filed Jan. 21, 2000 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 09/636,369 filed Aug. 11, 2000 and entitled “SYSTEMS AND METHODS FOR REMOTE MONITORING AND MODULATION OF MEDICAL DEVICES”; and U.S. application No. 09/916,858 filed Jul. 27, 2001 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS,” as well as issued patents including U.S. Pat. No. 6,001,067 issued Dec. 14, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. Pat. No. 4,994,167 issued Feb. 19, 1991 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; and U.S. Pat. No. 4,757,022 filed Jul. 12, 1988 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; U.S. application Ser. No. 60/489,615 filed Jul. 23, 2003 and entitled “ROLLED ELECTRODE ARRAY AND ITS METHOD FOR MANUFACTURE”; U.S. application Ser. No. 60/490,010 filed Jul. 25, 2003 and entitled “INCREASING BIAS FOR OXYGEN PRODUCTION IN AN ELECTRODE ASSEMBLY”; U.S. application Ser. No. 60/490,208 filed Jul. 25, 2003 and entitled “ELECTRODE ASSEMBLY WITH INCREASED OXYGEN GENERATION”; U.S. application Ser. No. 60/490,007 filed Jul. 25, 2003 and entitled “OXYGEN-GENERATING ELECTRODE FOR USE IN ELECTROCHEMICAL SENSORS”; U.S. application Ser. No. ______/______,______ filed on even date herewith and entitled “ROLLED ELECTRODE ARRAY AND ITS METHOD FOR MANUFACTURE”; U.S. application Ser. No. ______/______,______ filed on even date herewith and entitled “INCREASING BIAS FOR OXYGEN PRODUCTION IN AN ELECTRODE ASSEMBLY”; U.S. application Ser. No. ______/______,______ filed on even date herewith and entitled “ELECTRODE ASSEMBLY WITH INCREASED OXYGEN GENERATION”; U.S. application Ser. No. ______/______,______ filed on even date herewith and entitled “ELECTRODE SYSTEMS FOR ELECTROCHEMICAL SENSORS”. The foregoing patent applications and patents are incorporated herein by reference in their entireties.
All references cited herein are incorporated herein by reference in their entireties. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention as embodied in the attached claims.